Objective: To verify the influence of age on the prognosis of cervix carcinoma. Study design: Five hundred and sixty eight patients treated for a FIGO stage IB-IVA with radical irradiation in the Centre Hospitalier Universitaire Vaudois of Lausanne were subdivided according to the following age categories: _<45, 46-60, 61-69 and > 70 years. Taking the 46-60 years age group as the reference, the hazard ratios (HR) of death and corresponding 95% confidence intervals (95% CI) were estimated by means of a Cox multivariate analysis. Results: The 5-year survival rates were, respectively, 57%, 67%, 60% and 45%. For the youngest women the risk of death was significantly increased (HR = 2.00, 95% CI [1.32-3.00]) and was even more accentuated in advanced stages. Conclusion: Age under 45 years is a bad prognostic factor in carcinoma of the cervix.
Introduction
Several authors have reported that invasive carcinoma of the cervix had a poorer prognosis in younger patients than in older ones [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Others found no effect of age [15] [16] [17] [18] [19] [20] [21] [22] [23] . The potential difference in survival experience depending on age may have implications on the therapeutic approach, which so far has not been differentiated. In this report, we analyse a consecutive series of patients who attended a major Swiss University Hospital.
Patients and methods

Database
From January 1971 to December 1992, 642 consecutive patients with primary FIGO stage IB-IV carcinoma of the cervix were treated in the Centre Hospitalier Universitaire Vaudois, Lausanne. Only 568 of them were considered for the current study. Of the 74 * Corresponding author, Tel.: +21 3143269; fax: +21 3143263. patients excluded, 20 did not receive radiation therapy, 31 had incomplete baseline data, and 23 were lost to follow-up. Patients characteristics are summarized in Table 1 . Baseline evaluation for FIGO classification included pelvic examination under local or general anesthesia, cervical biopsies, cystoscopy, rectoscopy, chest X-ray, intravenous pyelogram or computerized tomography. Variables available on all patients were age, FIGO stage, histology, surgery, radiation therapy duration and decade of treatment. Age has been subdivided as follows: _<45, 46-60, 61-69 and >70 years. The median age is 60 years (range 20-90 years).
Surgery
One hundred and seventy-four patients with stage IB-IIA tumor underwent a radical hysterectomy with pelvic lymphadenectomy before radiation therapy.
Radiation therapy
Post-operative radiation therapy was decided because of positive margins, positive lymph nodes or vascular invasion.
0301-2115/96/$15.00 © 1996 Elsevier Science Ireland Ltd. All rights reserved SSD1 0028-2243(95)02290-N (27) 35 (24) 40 (29) 145 (26) Number in parentheses is percentage of column External radiation therapy was delivered initially with a betatron and in subsequent years with a linear accelerator. The pelvic volume was approached using a four-field box technique tailored in function of local extent of the tumor. The dose per fraction generally was 180-200 cGy/fraction, 5 days per week. Reference point was ICRU point. Patients with stage IB-IIA received 45 Gy to the whole pelvis. Patients with non-operable stage IIB-IIIB received 45 Gy to the whole pelvis and a 10-15 Gy boost to one or both parameters.
Intracavitary curietherapy delivered a boost of 30 Gy to point A or 45 Gy to the vaginal cuff (when a hysterectomy was performed), using an intra-uterine probe or a vaginal ovoid. The rectal dose was measured during the insertion of the source and the total rectal dose for the whole period of brachytherapy was computed. In the first decade (1971-79), low dose-rate curietherapy (LDR) was systematically used, whereas from the second decade on all patients were submitted to high doserate (HDR). The isotope used for LDR was radium, and the isotope used for HDR was cesium.
External radiation therapy and intracavitary curietherapy were performed concomitantly (Con) or sequentially (Seq). Sequential curietherapy was given at weekly intervals, 5-20 days following completion of external radiation. From 1990 to 1993, radiation therapy was Seq in 94% of the patients. This distribution is less homogeneous for decades 1970-79 (2%) and 1980-89 (36%).
Radiation therapy duration
This included the duration of external radiation therapy, the time interval between the former and brachytherapy, and the duration of brachytherapy. Therapy duration was calculated in days. Median therapy duration was 44 days. For the purpose of the analysis, patients were classified according to whether they had rather long therapies, taking 58 days (the 75th percentile) as an arbitrary cut-off. It is generally recognized that radiation therapy given over extended time interval is associated with reduced survival. [24] [25] [26] .
Stat&tical methods
The primary endpoint of this study was overall survival (OS), which was defined as time from beginning of radiation therapy to death due to any cause. Survival status for all patients was updated during Summer of 1993.
Statistical analyses were carried out by means of the software package Stata [27] . Survival percentages over time have been calculated by the Kaplan-Meier method [28] and their corresponding standard errors (S.E.) with Greenwood's formula [29] . For univariate analysis of OS the P-values from the log-rank test are reported for each comparison considered [30] . Estimated hazard ratios (HR) of death, with respect to the indicated reference group, their 95% confidence intervals (95% C1) and P-values were calculated with multivariate proportional-hazard-regression-model [31 ] . The following variables, coded into binary indicators to reflect the same subgroups shown in the tables, were included in the multivariate analysis: FIGO stage, histology, surgery, duration of therapy and decade of treatment. Values of HR greater than unity indicate increased rates of death with respect to the chosen reference category. For analyses other than on OS, chi-squared tests for independence have been used [32] . All probability values were for twosided tests.
For the purpose of the analyses of survival, observations have been censored at 5 years in order to limit the effect of competing causes of mortality (cause of death was not known with certainty) and also to avoid having only patients registered during the earlier periods contribute to the right tail of the survival curves. Five-year survival was considered a relevant endpoint for cervical cancer patients.
Results
As concerns the distribution of various characteristics according to age, we have observed a higher percentage of stage IB patients in the age group under 45, and a decreasing percentage of women having undergone surgery with increasing age. On the other hand, the frequency of histologic subtypes and of radiation therapy duration was consistent across age groups. Age distribution did not vary across decades.
A total of 71 patients developed pelvic recurrence and a total of 101 patients developed distant metastasis. In 27 women both events have been observed. The 5-year survival rates were, respectively, 57 ± 5% for the ___ 45-year group, 67 ± 5% for the 46-60-year group, 60 ± 4% for the 61-69-year group, and 45 ± 5% for the _> 70-year group.
An analysis based on the Cox model including only age has been used to estimate the HRs for each age group and the results are reported in Table 2 . A similar analysis has been performed for each of the other available variables and only stage was shown to be a statistically significant predictor of survival, more advanced stages being at higher risk of death. Age being the factor of primary interest, a multivariate analysis has been performed in order to assess its role allowing for the potential confounding effect of the other covariates.
The results are displayed in Table 3 only for age and suggest a U-shaped relationship between increasing age and risk of death. In particular, women aged 45 years or less were exposed to the highest risk of death, namely the double of the risk of the 46-60 years group (HR = 2.00, 95% CI [1.32-3.01]). After 60 years, the risk of death increased with increasing age, but never reached the level observed in the youngest group. The role of stage was also confirmed by the multivariate analysis. We have investigated whether the effect of age was constant within each group of women determined by the stage of the disease. An exploratory multivariate regression has been performed within each stage subgroup in order to compare the survival of women aged 45 or less to all other. The results are reported in Table 4 . Younger women were always at a higher risk of death than older women, but their risk increased with increasing stage. In the subgroup of stage III, women aged 45 or less had a more than double risk of death (HR = 2.28, 95% CI [1.26-4.11] ) than older women. Similarly, in the subgroup of stage IV there was an indication of a live-fold increase in the risk of death for younger women (HR = 5.15, 95% CI [1.21-21.9] ). These results have to be interpreted with caution due to their exploratory nature and to the small size of the groups, particularly so for stage IV.
Discussion
Some authors have reported a positive association between age and risk of death, which could not just be attributed to the obvious shorter life expectancy of the elderly [11. More often, however, a higher risk tbr younger women has been observed [1,3,6,13,141 Our results suggest that younger women are at increased risk of death. The observation that this risk increases when the disease is diagnosed at an advanced stage may imply that the disease is more aggressive in younger women. In this study, we do not have available reliable classification of cause of death and, therefore, we cannot assess whether younger women differ from older women in this respect. We cannot exclude either that our results are biased by the retrospective nature of the study and that our observations could be attributable to some confounders that we have not allowed for. The age-specific mortality rate of the cervix carcinoma for younger women cannot be attributed to a new papilloma virus epidemic during the last 20 years, since Sebbelov et al. have shown that the proportion of HPV positive patients is equal in all age groups [35] . Moreover, this age-specific mortality rate cannot be accounted for by difference in intrinsic radiosensitivity [361. Apoptosis and/or Bcl-2 expression, p53 mutations, 1L-6 autocrine production, and ploidy should be investigated to determine the reasons of treatment resistance [37] [38] [39] [40] [41] [42] [43] . The ongoing research on potential doubling time (Tpot) in cervical cancer may shed some light on this issue [441. The knowledge of all these cellular and molecular mechanisms could potentially lead to the elaboration of new strategies for therapeutic approaches.
